Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Other

Xencor, Inc.

G.d. Searle LLC

Novartis Ag

Xoma Technology Ltd.

Bao-lu Chen

Maninder S Hora

Bret A Shirley

Susan Babuka

Minna Choe

Melanie Tellers

Robert F Halenbeck

Kirk William Johnson

Glenn J Dorin

Gary V Johnson

Hassan Madani

Mark E Gustafson

Michael Tsang

Gary S Bild

Gregory L Pattison

Bo H Arve

Rajsharan K Rana

John R Desjarlais

Gregory Alan Lazar

Sher Bahadur Karki

Seung Yup Chu

Lori Kunkel

Philip W Hammond

David F Carmichael

Xiaofeng Lu

Maninder S Hoba

Augustus O Okhamafe

Li Long

Mohammad Luqman

Chin-Yi Huang

Asha Yabannavar

Sang Hoon Lee

Kidisti Araya

Deborah Hurst

Isabel Zaror

Rejsharan K Bana

Raisharan K Rana

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

Optimized anti-CD30 antibodies

Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.

Antagonist anti-CD40 antibody pharmaceutical compositions

Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-&#x3b2;) and methods useful in their preparation are provided. The compositions comprise the IFN-&#x3b2; solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-&#x3b2; in pharmaceutical compositions, are provided.

HSA-free formulations of interferon-Beta

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

Antagonist anti-CD40 antibodies

An antibody that targets CD30, wherein the antibody comprises at least one modification relative to a parent antibody and the antibody binds with altered affinity to an FcgR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the anti-CD30 antibody.

HSA-free formulations of interferon-&#x3b2;

Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.

Stabilized liquid polypeptide-containing pharmaceutical compositions

Stabilized aqueous compositions of tissue factor pathway inhibitor (TFPI) or TFPI variants comprise a solubilizing agent, an antioxidant, and a buffer. The combination of a solubilizing agent and an antioxidant can lead to a significant improvement in the storage life of TFPI or TFPI variant compositions. The solubilizing agent and antioxidant substantially counteract the effects of TFPI or TFPI variant degradation through aggregation and oxidation.

Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins

HSA-free formulations of interferon-beta

Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations.

Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor

Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.

A method of modifying protein solubility employs polyionic polymers. These facilitate the solubilization, formulation, purification and refolding of proteins especially incorrectly folded proteins and aggregated proteins. Compositions are described that are suitable for formulating TFPI. The compositions allow preparation of pharmaceutically acceptable compositions of TFPI at concentrations above 0.2 mg/mL and above 10 mg/mL.

Growing community of inventors

San Ramon, CA, United States of America

Bao-lu Chen